Boston Trust Walden Corp Purchases Shares of 539,639 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Boston Trust Walden Corp bought a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 539,639 shares of the company's stock, valued at approximately $26,189,000. Boston Trust Walden Corp owned 1.10% of Amphastar Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. GAMMA Investing LLC boosted its position in Amphastar Pharmaceuticals by 70.0% during the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company's stock worth $32,000 after buying an additional 273 shares during the period. Crossmark Global Holdings Inc. lifted its position in shares of Amphastar Pharmaceuticals by 2.5% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 11,300 shares of the company's stock worth $452,000 after purchasing an additional 275 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Amphastar Pharmaceuticals by 20.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company's stock worth $85,000 after purchasing an additional 301 shares during the period. Blue Trust Inc. lifted its position in shares of Amphastar Pharmaceuticals by 23.9% in the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company's stock worth $70,000 after purchasing an additional 309 shares during the period. Finally, nVerses Capital LLC lifted its position in shares of Amphastar Pharmaceuticals by 18.2% in the 3rd quarter. nVerses Capital LLC now owns 2,600 shares of the company's stock worth $126,000 after purchasing an additional 400 shares during the period. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Stock Up 1.3 %

Shares of NASDAQ AMPH traded up $0.66 during trading on Friday, hitting $50.29. The stock had a trading volume of 179,571 shares, compared to its average volume of 395,258. Amphastar Pharmaceuticals, Inc. has a 12 month low of $36.56 and a 12 month high of $65.92. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.52 and a quick ratio of 2.63. The company has a market capitalization of $2.46 billion, a PE ratio of 17.40, a PEG ratio of 0.88 and a beta of 0.83. The firm has a fifty day moving average of $47.90 and a two-hundred day moving average of $43.51.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.10. The firm had revenue of $182.39 million during the quarter, compared to analyst estimates of $171.29 million. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. As a group, equities research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.71 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on AMPH shares. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Piper Sandler dropped their target price on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating on the stock in a research report on Thursday, August 8th. Finally, StockNews.com upgraded shares of Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Friday, October 18th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $63.00.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 17,101 shares of the company's stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $43.07, for a total transaction of $736,540.07. Following the sale, the director now directly owns 33,971 shares of the company's stock, valued at $1,463,130.97. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, Director Richard K. Prins sold 17,101 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $43.07, for a total value of $736,540.07. Following the sale, the director now directly owns 33,971 shares of the company's stock, valued at approximately $1,463,130.97. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO William J. Peters sold 10,282 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $44.23, for a total transaction of $454,772.86. Following the completion of the sale, the chief financial officer now directly owns 94,103 shares in the company, valued at approximately $4,162,175.69. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,383 shares of company stock valued at $1,524,123 over the last three months. 27.10% of the stock is currently owned by insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.